Phase II Study Evaluating the Efficacy and Safety of KX-826

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

July 8, 2021

Study Completion Date

August 18, 2021

Conditions
Androgenetic Alopecia (AGA)
Interventions
DRUG

KX-826-2.5 mg (0.25%)/60 mL BID

Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.

DRUG

KX-826-5 mg (5%)/60 mL QD

Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.

DRUG

KX-826-5 mg (5%)/60 mL BID

Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.

OTHER

Placebo

Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.

Trial Locations (9)

Unknown

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Dermatology Hospital of Southern Medical University, Guangzhou

Guangdong Provincial People's Hospital, Guangzhou

Affiliated Hospital of Jiangsu University, Zhenjiang

Huashan Hospital, Shanghai

Shanghai Dermatology Hospital, Shanghai

Tianjin Medical University General Hospital, Tianjin

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT05940506 - Phase II Study Evaluating the Efficacy and Safety of KX-826 | Biotech Hunter | Biotech Hunter